Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs Consumer Staples Select Sector SPDR Fund — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.69 (market cap $58.74B), while Consumer Staples Select Sector SPDR Fund trades at $83.19 (market cap $13.50B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 4.4× Consumer Staples Select Sector SPDR Fund's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Consumer Staples Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| TAK | XLP | |
|---|---|---|
Market Cap | $58.74B | $13.50B |
Volume | 3,110,994 | 14,599,953 |
Sector | Health | — |
52-Week High | $19.05 | $90.00 |
52-Week Low | $13.23 | $75.61 |
Typical Hold Time | 0 Days | 72 Days |
Enterprise Value | $86.65B | — |
Dividend Yield | 3.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XLP (Consumer Staples Select Sector SPDR ETF) trades at $83.21, up 1.85% with bullish technical signals from moving averages and oscillators. The ETF has gained 6.6% year-to-date, outperforming consumer discretionary stocks. Analyst consensus is strongly positive with 100% buy ratings. Recent news highlights XLP's defensive characteristics amid economic uncertainty and its competitive expense ratio advantage over peers.
The outlook remains favorable given XLP's defensive positioning in consumer staples, though rising interest rates pose a headwind. Investment opportunity lies in the ETF's stability during market volatility, while risks include persistent inflation pressures and potential consumer spending slowdown. The technical setup suggests continued upward momentum with support at $82-83 levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
